<i>In situ</i> repolarization of tumor-associated macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy

Ruhua Luo; Zhongyu Yue; Qian Yang; Honghua Zhang; Tian Xie; Shuling Wang; Qingchang Tian

doi:10.1016/j.jpha.2024.01.009

Volume 14 Issue 8

Aug. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > 14(8): 100941

Ruhua Luo, Zhongyu Yue, Qian Yang, Honghua Zhang, Tian Xie, Shuling Wang, Qingchang Tian. In situ repolarization of tumor-associated macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy[J]. Journal of Pharmaceutical Analysis, 2024, 14(8): 100941. doi: 10.1016/j.jpha.2024.01.009

Citation:

Ruhua Luo, Zhongyu Yue, Qian Yang, Honghua Zhang, Tian Xie, Shuling Wang, Qingchang Tian. In situ repolarization of tumor-associated macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy[J]. Journal of Pharmaceutical Analysis, 2024, 14(8): 100941. doi: 10.1016/j.jpha.2024.01.009

Citation:

PDF( 2542 KB)

In situ repolarization of tumor-associated macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy

doi: 10.1016/j.jpha.2024.01.009

Ruhua Luo^a,b,c,
Zhongyu Yue^a,b,
Qian Yang^a,b,
Honghua Zhang^a,b,
Tian Xie^{a,b
,
,},
Shuling Wang^{a,b
,
,},
Qingchang Tian^{a,b
,
,}

a. School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China;
b. Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China;
c. Department of Pharmacy, Hankou Hospital, Wuhan, 430012, China

Funds:

This work was supported by Zhejiang Provincial Natural Science Foundation of China (Grant No.: LY20H160008), the Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China (Grant No.: LHDMZ22H300001), and National Natural Science Foundation of China (Grant No.: 82074052).

Received Date: Jul. 22, 2023
Accepted Date: Jan. 29, 2024
Rev Recd Date: Jan. 26, 2024
Publish Date: Feb. 02, 2024

Abstract

FullText(HTML)

References(4)

References

[1]	J.A. Joyce, D.T. Fearon, T cell exclusion, immune privilege, and the tumor microenvironment, Science 348(2015) 74-80.
[2]	R. Noy, J.W. Pollard, Tumor-associated macrophages: From mechanisms to therapy, Immunity 41(2014) 49-61.
[3]	R. Sumitomo, T. Hirai, M. Fujita, et al., PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer, Lung Cancer 136(2019) 136-144.
[4]	B. Zhai, N. Zhang, X. Han, et al., Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review, Biomed. Pharmacother. 114(2019), 108812.